CTOs on the Move

Homeward Health

www.homewardhealth.com

 
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Homeward Health raised $20M on 03/07/2022

Similar Companies

Inteleso

Inteleso is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nexeon MedSystems

Nexeon MedSystems is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micromedex

Micromedex is a Greenwood Vlg, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Place for Children with Autism

The Place for Children with Autism provides a comprehensive approach to autism treatment that focuses on the highest quality therapy to enrich the lives of children with autism and their families across all communities. Utilizing one-to-one ABA therapy in a structured, center-based environment, our programs are designed with quality as the priority and support as the ongoing means to achieve it. We specialize in all developmental areas to help children build independence and school readiness skills to succeed. The Place for Children with Autism works with families from all economic backgrounds to find options that fit their needs.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.